Navigation Links
Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks
Date:2/22/2010

LOS ANGELES, Feb. 22 /PRNewswire/ -- Ritter Pharmaceuticals (www.ritterpharmaceuticals.com), a company dedicated to helping individuals live a healthier and happier life style through improved digestion, announced today that it will join the leading lactose intolerance experts around the country at the NIH Consensus Development Conference for Lactose Intolerance and Health in Bethesda, Maryland from February 22-24. The event will discuss topics regarding lactose intolerance and will be focused on answering questions such as the prevalence of lactose intolerance and health outcomes of diets which exclude dairy products.

Today, a significant concern among individuals, including healthcare providers, is that avoidance of dairy products leads to insufficient intake of calcium, vitamin D, and other nutrients. These deficiencies may cause weaker bone health, increased risk of bone fractures, osteoporosis and more serious issues such as hypertension, breast cancer, and colon cancer. Despite the risks associated with a dairy exclusion diet, 70% of the time physicians still recommend dairy avoidance to manage symptoms of lactose intolerance.(1)

"Making sure people eat adequate amounts of dairy is essential, but many lactose intolerant individuals do not choose to do so because of painful or uncomfortable symptoms," said Dennis Savaiano, Ph.D., Dean of the College of Consumer and Family Sciences, Foods and Nutrition at Purdue University and speaker at the upcoming NIH conference.

"Lactagen®, a product unlike any other on the market, is a dietary supplement program taken over 38 days, developed to help reduce symptoms of lactose intolerance," said Andrew Ritter, President and CEO of Ritter Pharmaceuticals, the makers of Lactagen®.  "Clinical data as well as our customers surveyed have shown that Lactagen® is nearly 80% effective at significantly reducing lactose intolerance symptoms."

Lactase supplements often prove to be ineffective or unreliable as reported in a recent study showing that only 26% of lactose intolerant individuals were satisfied with taking lactase supplements.(1)

About Ritter Pharmaceuticals

Ritter Pharmaceuticals is dedicated to helping individuals live a healthier and happier life style through improved digestion.  Ritter Pharmaceuticals focuses on the discovery, development and commercialization of innovative therapeutic treatments for gastrointestinal diseases and conditions.  One of these products is Lactagen®, a dietary supplement developed to help reduce symptoms of lactose intolerance.

(1) "Physicians' and Payors' Perception and Intended Use to Treat Lactose Intolerance." Study performed by Engage Health, June, 2008.

SOURCE Ritter Pharmaceuticals

Back to top

RELATED LINKS
http://www.ritterpharmaceuticals.com/
http://www.lactagen.com

'/>"/>

SOURCE Ritter Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
2. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
3. Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
4. Transdel Pharmaceuticals Announces Management Reorganization
5. Merz Pharmaceuticals Introduces New Mederma(R) Stretch Marks Therapy Now Available in Drugstores Nationwide
6. GlaxoSmithKline President of North America Pharmaceuticals, Deirdre Connelly, Named 2010 Woman of the Year by the Healthcare Businesswomens Association
7. Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
8. Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
9. Endo Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on February 22, 2010
10. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
11. ISTA Pharmaceuticals Announces 2010 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/9/2016)... Calif. , Feb. 9, 2016 /PRNewswire/ - Nevro ... company that is providing innovative evidence-based solutions for the ... release financial results for the fourth quarter and full ... 29, 2016. Company management will host a conference call ... Time) on Monday, February 29, 2016. www.nevro.com ...
(Date:2/9/2016)... 9, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today reported its fourth quarter and full year ... vivo therapeutic genome editing," said Edward Lanphier, ... finger nuclease (ZFN) technology leads the therapeutic genome ... competencies necessary to move our ground-breaking genome editing ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. Clevens, MD, ... to welcome a new addition to their growing practice. Beginning this month, Teresa ... nurse practitioner performing cosmetic procedures including injectables, fillers and laser treatments. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Steven Douglas Associates is a ... Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s Your Taste ... This year the event will be held in a new, more causal format at ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: ... stores, announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, ... at the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic ...
Breaking Medicine News(10 mins):